← Eichor
Condition: Gliosarcoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Gliosarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV G
Phase 1 · 2 location(s) · Jonsson Comprehensive Cancer Center · NCT07089641hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
Phase 2 · 1 location(s) · Leland Metheny · NCT05052957Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Phase 2 · 1 location(s) · Northwestern University · NCT05864534Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
Phase N/A · 1 location(s) · Baptist Health South Florida · NCT05756985Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
Phase N/A · 2 location(s) · Sied Kebir · NCT06954636Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Phase 2 · 1 location(s) · Mayo Clinic · NCT05465954Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Phase 1 · 1 location(s) · Florida International University · NCT05857969Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Phase 1 · 11 location(s) · Memorial Sloan Kettering Cancer Center · NCT06934889A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Phase 1 · 1 location(s) · University of Nebraska · NCT05698524Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT04991870GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma an
Phase 2 · 1 location(s) · Mayo Clinic · NCT07301268MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03896568Study of Pembrolizumab and M032 (NSC 733972)
Phase 1/Phase 2 · 1 location(s) · University of Alabama at Birmingham · NCT05084430Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Phase 1 · 1 location(s) · Jazz Pharmaceuticals · NCT04541082A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the S
Phase 1 · 1 location(s) · University College, London · NCT07134842HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Phase 1 · 3 location(s) · M.D. Anderson Cancer Center · NCT03911388
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.